Prosecution Insights
Last updated: April 19, 2026

Examiner: RAMIREZ, DELIA M

Tech Center 1700 • Art Units: 1652 1799

This examiner grants 65% of resolved cases

Performance Statistics

64.9%
Allow Rate
At TC average
891
Total Applications
+56.5%
Interview Lift
1006
Avg Prosecution Days
Based on 838 resolved cases, 2023–2026

Rejection Statute Breakdown

6.9%
§101 Eligibility
19.5%
§102 Novelty
19.8%
§103 Obviousness
38.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16973061 CRISPR EFFECTOR SYSTEM BASED AMPLIFICATION METHODS, SYSTEMS, AND DIAGNOSTICS Final Rejection PRESIDENT AND FELLOWS OF HARVARD COLLEGE
17786913 BIOSYNTHETIC PLATFORM FOR THE PRODUCTION OF CANNABINOIDS AND OTHER PRENYLATED COMPOUNDS Final Rejection The Regents of the University of California
17998703 IMPROVED METHOD FOR THE PRODUCTION OF ISOPRENOIDS Final Rejection BASF SE
18297366 DETERGENT COMPOSITIONS CONTAINING ENZYMES Final Rejection The Procter & Gamble Company
16771794 USE OF A COMBINATION OF TET EXOPROTEASES OBTAINED FROM EXTREMOPHILIC MICROORGANISMS FOR HYDROLYZING POLYPEPTIDES Final Rejection UNIVERSITE GRENOBLE ALPES
17331883 Engineered CRISPR-Cas9 Nucleases Final Rejection The General Hospital Corporation
17924145 GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING ORGANIC ACID Final Rejection TORAY INDUSTRIES, INC.
18402269 DECOLORIZING COMPOSITION INCLUDING DICYANDIAMIDE AND HYDROGEN PEROXIDE AND DECOLORIZING METHOD USING THE SAME Non-Final OA CJ CHEILJEDANG CORPORATION
17459166 ENGINEERED PROTEINS AND METHODS OF USE THEREOF Non-Final OA Pairwise Plants Services, Inc.
18718677 PRODUCTION OF ALPHA-1,3-FUCOSYLATED COMPOUNDS Non-Final OA INBIOSE N.V.
17961007 BACILLUS GIBSONII-CLADE SERINE PROTEASES Final Rejection Danisco US Inc.
18035610 METHOD FOR ENZYMATIC OXIDATION OF SULFINIC ACIDS TO SULFONIC ACIDS Final Rejection WACKER CHEMIE AG
16450699 NOVEL CRISPR ENZYMES AND SYSTEMS Non-Final OA The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
16450852 NOVEL CRISPR ENZYMES AND SYSTEMS Final Rejection The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
16450825 NOVEL CRISPR ENZYMES AND SYSTEMS Final Rejection The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
18627530 GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF Final Rejection Beijing University of Chemical Technology
18013047 Improved Export of Oligosaccharides From Bacterial Cells Non-Final OA Chr. Hansen A/S
18501492 SYSTEM AND METHOD FOR PRODUCING A SUGAR STREAM Non-Final OA Fluid Quip Technologies, LLC
18501501 METHOD FOR PRODUCING A SUGAR STREAM Non-Final OA Fluid Quip Technologies, LLC
18242912 MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BIOSYNTHESIZED TARGET PRODUCTS HAVING REDUCED LEVELS OF BYPRODUCTS Non-Final OA Genomatica, Inc.
18548429 NOVEL CRISPR-CAS NUCLEASES FROM METAGENOMES Non-Final OA Brain Biotech AG
18548325 INSECT-DERIVED ASPARTATE DECARBOXYLASES AND VARIANTS THEREOF FOR IMPROVED BETA-ALANINE PRODUCTION Non-Final OA MOJIA BIOTECH LTD.
17911409 BIO-BASED NYLON PRECURSORS HAVING REDUCED ORGANIC AND INORGANIC IMPURITIES Non-Final OA MOJIA BIOTECH LTD.
17277585 PROCESS FOR CONTROLLING A FERMENTATION PROCESS Non-Final OA FermentationExperts A/S
18033787 Novel Variants of Endonuclease V and Uses Thereof Non-Final OA DNA Script
18003025 PICHIA CIFERRII MUTANT STRAIN HAVING IMPROVED SPHINGOLIPID AND SPHINGOID BASE PRODUCTIVITY, AND PREPARATION METHOD THEREFOR Non-Final OA Croda Korea Ltd
17926572 PROCESS FOR EXTRACTING A HYALURONIC ACID FROM A FUNGUS, A HYALURONIC ACID OF PLANT ORIGIN AND USE THEREOF Final Rejection VIVATIS PHARMA GMBH
17270690 Method for Producing Biodegradable Polymer Non-Final OA MOHARRAM VENTURES INC.
15561524 EXPRESSION SYSTEM AND USES THEREOF Non-Final OA SELEXIS S.A.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month